Michael Chi Sells 17,304 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Michael Chi sold 17,304 shares of the company’s stock in a transaction on Friday, January 24th. The stock was sold at an average price of $31.00, for a total transaction of $536,424.00. Following the completion of the transaction, the insider now directly owns 193,601 shares of the company’s stock, valued at $6,001,631. This represents a 8.20 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Michael Chi also recently made the following trade(s):

• On Friday, January 10th, Michael Chi sold 7,259 shares of Hims & Hers Health stock. The shares were sold at an average price of $24.07, for a total value of $174,724.13.
• On Tuesday, December 24th, Michael Chi sold 17,303 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.97, for a total value of $483,964.91.
• On Thursday, December 19th, Michael Chi sold 7,500 shares of Hims & Hers Health stock. The shares were sold at an average price of $26.00, for a total transaction of $195,000.00.
• On Tuesday, December 10th, Michael Chi sold 7,259 shares of Hims & Hers Health stock. The stock was sold at an average price of $32.25, for a total transaction of $234,102.75.
• On Monday, December 2nd, Michael Chi sold 2,054 shares of Hims & Hers Health stock. The shares were sold at an average price of $33.56, for a total transaction of $68,932.24.

Hims & Hers Health Stock Down 0.0 %

Shares of NYSE:HIMS traded down $0.00 during midday trading on Friday, reaching $30.89. The company’s stock had a trading volume of 8,946,218 shares, compared to its average volume of 10,210,918. The firm has a market capitalization of $6.75 billion, a PE ratio of 70.20 and a beta of 1.31. The stock has a fifty day moving average of $27.98 and a 200 day moving average of $22.09. Hims & Hers Health, Inc. has a twelve month low of $8.51 and a twelve month high of $35.02.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. During the same quarter last year, the business posted ($0.04) EPS. The company’s revenue was up 77.1% on a year-over-year basis. Sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently issued reports on HIMS shares. Deutsche Bank Aktiengesellschaft upped their price objective on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a report on Wednesday, November 6th. Needham & Company LLC increased their price objective on shares of Hims & Hers Health from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Monday, January 6th. Morgan Stanley initiated coverage on shares of Hims & Hers Health in a report on Tuesday, December 17th. They issued an “overweight” rating and a $42.00 target price on the stock. TD Cowen reaffirmed a “buy” rating and issued a $28.00 price target on shares of Hims & Hers Health in a report on Wednesday, November 20th. Finally, Canaccord Genuity Group lifted their price target on Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a research report on Monday, December 2nd. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, Hims & Hers Health currently has a consensus rating of “Hold” and a consensus price target of $25.13.

Institutional Investors Weigh In On Hims & Hers Health

A number of hedge funds and other institutional investors have recently made changes to their positions in HIMS. Main Management ETF Advisors LLC purchased a new stake in Hims & Hers Health during the third quarter worth $672,000. Robeco Institutional Asset Management B.V. purchased a new stake in shares of Hims & Hers Health during the 3rd quarter worth about $604,000. Carnegie Investment Counsel acquired a new stake in shares of Hims & Hers Health during the 3rd quarter valued at about $5,531,000. Royce & Associates LP increased its stake in shares of Hims & Hers Health by 17.0% in the 3rd quarter. Royce & Associates LP now owns 341,000 shares of the company’s stock valued at $6,281,000 after purchasing an additional 49,500 shares in the last quarter. Finally, Versor Investments LP purchased a new position in shares of Hims & Hers Health in the 3rd quarter valued at about $634,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.